Condition: Glaucoma · Open-Angle Glaucoma · Ocular Hypertension · Sponsor: University of Miami
The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.
This description comes directly from the study's public registry record.
Javier Paredes, BA, MBA · 305-326-6387 · jxp2537@med.miami.edu
Monica Arango, BA · 305-326-6351 · mrarango@med.miami.edu
Always discuss trial participation with your own doctor first.
| Bascom Palmer Eye Institute | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07217678